Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for stage III lung cancer? trial adds experimental drug to standard care

NCT ID NCT06667908

Disease control Sponsor: Johnson & Johnson Enterprise Innovation Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation and a follow-up immunotherapy (durvalumab) can shrink tumors more effectively in people with locally advanced, inoperable stage III non-small cell lung cancer. About 130 participants will receive either the standard treatment or the standard plus the new drug. The main goal is to see if more tumors shrink significantly with the added drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening * Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization * Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification * Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 Exclusion Criteria: * Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression * Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV * Another concurrent or prior primary malignancy within the last 36 months at informed consent * Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab * History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    43 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Antoni van Leeuwenhoek

    RECRUITING

    Amsterdam, 1066 CX, Netherlands

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Clinica Univ. de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • Dongguan People s Hospital

    RECRUITING

    Dongguan, 523109, China

  • Emory University Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30306, United States

  • FirstHealth of the Carolinas

    RECRUITING

    Pinehurst, North Carolina, 28374, United States

  • Fundacao Pio XII

    RECRUITING

    Barretos, 14784 400, Brazil

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Hopital De La Cavale Blanche

    RECRUITING

    Brest, 29200, France

  • Hopital Nord Marseille

    RECRUITING

    Marseille, 13015, France

  • Hopital Tenon

    RECRUITING

    Paris, 75020, France

  • Hosp. Clinico Univ. de Santiago

    RECRUITING

    Santiago de Compostela, 15706, Spain

  • Hosp. Univ. 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hosp. Univ. I Politecni La Fe

    RECRUITING

    Valencia, 46026, Spain

  • Institut Curie

    RECRUITING

    Paris, 75248, France

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Macquarie University

    RECRUITING

    North Ryde, 2109, Australia

  • Marmara University Pendik Training Hospital

    RECRUITING

    Istanbul, 34899, Turkey (Türkiye)

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Moores Cancer Center at UC San Diego Health

    RECRUITING

    La Jolla, California, 92037, United States

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Oregon Health And Science University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Orlando Health Cancer Institute

    RECRUITING

    Orlando, Florida, 32806, United States

  • Prince of Wales Hospital

    RECRUITING

    Shatin, Hong Kong

  • Radboud Umcn

    RECRUITING

    Nijmegen, 6525 GA, Netherlands

  • Royal Brisbane and Women's Hospital

    RECRUITING

    Herston, 4029, Australia

  • Royal Melbourne Hospital

    RECRUITING

    Parkville, 3050, Australia

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Sakarya University Training and Research Hospital

    RECRUITING

    Sakarya, 54100, Turkey (Türkiye)

  • Sir Charles Gairdner Hospital

    RECRUITING

    Nedlands, 6009, Australia

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    RECRUITING

    São Paulo, 05651 901, Brazil

  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes

    RECRUITING

    São Paulo, 01308 050, Brazil

  • The Affiliated Cancer Hospital of Shandong First Medical University

    RECRUITING

    Jinan, 250117, China

  • The First Affiliated Hospital Sun Yat sen University

    RECRUITING

    Guangzhou, 510080, China

  • University College London Hospitals

    RECRUITING

    London, NW1 2BU, United Kingdom

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University of Connecticut Health Center

    RECRUITING

    Farmington, Connecticut, 06030, United States

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Vermont Medical Center

    RECRUITING

    Burlington, Vermont, 05401, United States

  • Washington University in St Louis

    RECRUITING

    St Louis, Missouri, 63130, United States

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.